FACTS: B1 Vitamins are being used to combat early and mild-symptoms of Alzheimer’s and dementia at the University of San Diego.
Alzheimer’s Disease Cooperative Study (ADCS) is actively recruiting approximately 400 patients at up to 50 clinical trial sites across the nation to record long-term affects of B1 vitamins of patients with Alzheimer’s disease (AD) and mild cognitive impairment because of AD (MCI). The clinical trials are to start in early 2023.
Gary E. Gibson, PhD, professor of neuroscience at Brain and Mind Research Institute, part of Weill Cornell Medicine, is investigating how the human body’s metabolism is being affected in early stages in Alzheimer’s and Dementia. Gibson sees change in glucose metabolism, the breakdown of carbohydrates into simple sugars, and he believes it is linked to a tissue deficiency of thiamine-regulated metabolic pathways linked to Alzheimer’s.
QUOTES: Gary E. Gibson, “At the Burke Neurological Institute, we have been studying the effects of thiamine on neuro-degenerative diseases for over 40 years. This important grant will allow us to test the treatment with hundreds of Alzheimer’s disease patients across the U.S. We are eager to begin this critical new stage of the research.”
SOURCE: UC San Diego News Center, click here.
BECOME A PATIENT: click here
